Ausgabe 11/2018
Special Issue: Monoamine Oxidase A and B: Eternally Enigmatic Isoenzymes
Inhalt (16 Artikel)
Introduction to the special issue on monoamine oxidase A and B: eternally enigmatic isoenzymes
Jean Chen Shih, Peter Riederer, Wakako Maruyama, Makoto Naoi
90 years of monoamine oxidase: some progress and some confusion
Keith F. Tipton
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy
Jean C. Shih
The structure of monoamine oxidases: past, present, and future
Luca Giacinto Iacovino, Francesca Magnani, Claudia Binda
Epigenetic signature of MAOA and MAOB genes in mental disorders
Christiane Ziegler, Katharina Domschke
From aggression to autism: new perspectives on the behavioral sequelae of monoamine oxidase deficiency
Marco Bortolato, Gabriele Floris, Jean C. Shih
Gene–environment interaction of monoamine oxidase A in relation to antisocial behaviour: current and future directions
Kent W. Nilsson, Cecilia Åslund, Erika Comasco, Lars Oreland
Monoamine oxidase-A, serotonin and norepinephrine: synergistic players in cardiac physiology and pathology
Jeanne Mialet-Perez, Yohan Santin, Angelo Parini
Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons
Makoto Naoi, Wakako Maruyama, Masayo Shamoto-Nagai
An inducible MAO-B mouse model of Parkinson’s disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics
Manish Chamoli, Shankar J. Chinta, Julie K. Andersen
Kinetics, mechanism, and inhibition of monoamine oxidase
Rona R. Ramsay, Alen Albreht
On the practical aspects of characterising monoamine oxidase inhibition in vitro
Andrew Holt
A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths
Peter Kenneth Gillman
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases
Moussa B. H. Youdim
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease
Éva Szökő, Tamás Tábi, Peter Riederer, László Vécsei, Kálmán Magyar
Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical–pharmacological aspects
Peter Riederer, Thomas Müller